Cellmid Signs Evaluation and Option to License Agreement with Zoetis
Complete the form below to unlock access to ALL audio articles.
Cellmid Limited has signed an agreement with Zoetis for the evaluation and option to license one of Cellmid’s anti-midkine antibodies (MK antibody) for therapeutic use in companion animals.
Cellmid’s proprietary MK antibodies have previously been shown to be effective in animal models of a number of diseases.
Zoetis has extensive experience in the development and commercialization of animal health products and will evaluate the performance of Cellmid’s MK antibody in their proprietary models with the view to license.
The agreement is exclusive for the use of Cellmid’s MK-antibody in animals. The terms of the agreement include upfront and exclusivity payments until such time as the option to license is exercised by Cellmid’s partner. Additional financial details of the agreement are not disclosed.
